Consolidated Statement of Shareholders' Equity (Unaudited) - 6 months ended Jun. 30, 2021 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning Balance at Dec. 31, 2020	$ 1	$ 48,453	$ (48,551)	$ (856)	$ (953)
Beginning Balance (Shares) at Dec. 31, 2020	111,429,532
Other comprehensive income				(345)	(345)
Issuance of shares to atai Life Sciences (net of transaction costs of $297)		8,398			8,398
Issuance of shares to atai Life Sciences (net of transaction costs of $297) (shares)	37,300,000
Issuance of warrants to atai Life Sciences (net of transaction costs of $125)		3,526			3,526
Conversion of convertible notes		321			321
Conversion of convertible notes (in shares)	1,048,229
Conversion of convertible debentures		289			289
Conversion of convertible debentures (in shares)	768,000
Stock-based compensation		56			56
Net loss for the period			(4,452)		(4,452)
Ending Balance at Jun. 30, 2021	$ 1	$ 61,043	$ (53,003)	$ (1,201)	$ 6,840
Ending Balance (Shares) at Jun. 30, 2021	150,545,761